STOCK TITAN

[Form 4] CareDx, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

On July 8, 2025, CareDx, Inc. (CDNA) director Michael Goldberg filed a Form 4 reporting receipt of 1,218 shares of common stock at a grant price of $0 under the company’s Outside Director Compensation Policy. The automatic equity award, issued in lieu of quarterly cash fees, raises his direct ownership to 154,216 shares. No open-market purchases, sales or derivative transactions were disclosed, indicating the filing is a routine governance matter rather than a signal of insider sentiment.

Il 8 luglio 2025, Michael Goldberg, direttore di CareDx, Inc. (CDNA), ha presentato un Modulo 4 segnalando la ricezione di 1.218 azioni ordinarie a un prezzo di assegnazione di 0$ secondo la politica di compensazione per direttori esterni della società. L'assegnazione automatica di azioni, concessa in sostituzione delle commissioni trimestrali in contanti, porta la sua partecipazione diretta a 154.216 azioni. Non sono stati comunicati acquisti, vendite o operazioni su derivati sul mercato aperto, indicando che la segnalazione è una questione di governance ordinaria e non un segnale di sentiment interno.

El 8 de julio de 2025, Michael Goldberg, director de CareDx, Inc. (CDNA), presentó un Formulario 4 informando la recepción de 1,218 acciones ordinarias a un precio de concesión de $0 bajo la Política de Compensación para Directores Externos de la compañía. La asignación automática de acciones, otorgada en lugar de honorarios trimestrales en efectivo, eleva su propiedad directa a 154,216 acciones. No se divulgaron compras, ventas o transacciones con derivados en el mercado abierto, lo que indica que la presentación es un asunto rutinario de gobernanza y no una señal del sentimiento interno.

2025년 7월 8일, CareDx, Inc.(CDNA)의 이사 마이클 골드버그가 회사의 외부 이사 보상 정책에 따라 0달러의 부여 가격으로 1,218주의 보통주를 수령했음을 보고하는 Form 4를 제출했습니다. 분기별 현금 수수료 대신 지급되는 자동 주식 보상으로 인해 그의 직접 보유 주식은 154,216주로 증가했습니다. 공개 시장에서의 매수, 매도 또는 파생상품 거래는 보고되지 않아 이번 제출이 내부자 심리의 신호가 아닌 일상적인 거버넌스 사안임을 나타냅니다.

Le 8 juillet 2025, Michael Goldberg, administrateur de CareDx, Inc. (CDNA), a déposé un formulaire 4 signalant la réception de 1 218 actions ordinaires à un prix d’attribution de 0 $ dans le cadre de la politique de rémunération des administrateurs externes de la société. Cette attribution automatique d’actions, accordée en remplacement des honoraires trimestriels en espèces, porte sa détention directe à 154 216 actions. Aucune transaction d’achat, de vente ou de dérivés sur le marché ouvert n’a été divulguée, ce qui indique que cette déclaration relève d’une procédure de gouvernance courante et non d’un signal sur le sentiment des initiés.

Am 8. Juli 2025 reichte Michael Goldberg, Direktor von CareDx, Inc. (CDNA), ein Formular 4 ein, in dem er den Erhalt von 1.218 Stammaktien zu einem Zuteilungspreis von 0 $ gemäß der Vergütungspolitik für externe Direktoren des Unternehmens meldete. Die automatische Aktienzuteilung, die anstelle von vierteljährlichen Barvergütungen gewährt wird, erhöht seinen direkten Besitz auf 154.216 Aktien. Es wurden keine Käufe, Verkäufe oder Derivatgeschäfte am offenen Markt offengelegt, was darauf hinweist, dass die Meldung eine routinemäßige Governance-Angelegenheit und kein Signal für Insiderstimmung ist.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine director stock grant; neutral signal for CDNA.

The 1,218-share award to Director Michael Goldberg represents about 0.8% of his 154k-share stake and less than 0.003% of CareDx’s shares outstanding. Because it is an automatic quarterly grant issued at $0, the transaction does not reflect proactive insider buying or selling pressure. As such, the Form 4 is unlikely to affect valuation, liquidity, or market sentiment; it mainly satisfies Section 16 reporting requirements.

Il 8 luglio 2025, Michael Goldberg, direttore di CareDx, Inc. (CDNA), ha presentato un Modulo 4 segnalando la ricezione di 1.218 azioni ordinarie a un prezzo di assegnazione di 0$ secondo la politica di compensazione per direttori esterni della società. L'assegnazione automatica di azioni, concessa in sostituzione delle commissioni trimestrali in contanti, porta la sua partecipazione diretta a 154.216 azioni. Non sono stati comunicati acquisti, vendite o operazioni su derivati sul mercato aperto, indicando che la segnalazione è una questione di governance ordinaria e non un segnale di sentiment interno.

El 8 de julio de 2025, Michael Goldberg, director de CareDx, Inc. (CDNA), presentó un Formulario 4 informando la recepción de 1,218 acciones ordinarias a un precio de concesión de $0 bajo la Política de Compensación para Directores Externos de la compañía. La asignación automática de acciones, otorgada en lugar de honorarios trimestrales en efectivo, eleva su propiedad directa a 154,216 acciones. No se divulgaron compras, ventas o transacciones con derivados en el mercado abierto, lo que indica que la presentación es un asunto rutinario de gobernanza y no una señal del sentimiento interno.

2025년 7월 8일, CareDx, Inc.(CDNA)의 이사 마이클 골드버그가 회사의 외부 이사 보상 정책에 따라 0달러의 부여 가격으로 1,218주의 보통주를 수령했음을 보고하는 Form 4를 제출했습니다. 분기별 현금 수수료 대신 지급되는 자동 주식 보상으로 인해 그의 직접 보유 주식은 154,216주로 증가했습니다. 공개 시장에서의 매수, 매도 또는 파생상품 거래는 보고되지 않아 이번 제출이 내부자 심리의 신호가 아닌 일상적인 거버넌스 사안임을 나타냅니다.

Le 8 juillet 2025, Michael Goldberg, administrateur de CareDx, Inc. (CDNA), a déposé un formulaire 4 signalant la réception de 1 218 actions ordinaires à un prix d’attribution de 0 $ dans le cadre de la politique de rémunération des administrateurs externes de la société. Cette attribution automatique d’actions, accordée en remplacement des honoraires trimestriels en espèces, porte sa détention directe à 154 216 actions. Aucune transaction d’achat, de vente ou de dérivés sur le marché ouvert n’a été divulguée, ce qui indique que cette déclaration relève d’une procédure de gouvernance courante et non d’un signal sur le sentiment des initiés.

Am 8. Juli 2025 reichte Michael Goldberg, Direktor von CareDx, Inc. (CDNA), ein Formular 4 ein, in dem er den Erhalt von 1.218 Stammaktien zu einem Zuteilungspreis von 0 $ gemäß der Vergütungspolitik für externe Direktoren des Unternehmens meldete. Die automatische Aktienzuteilung, die anstelle von vierteljährlichen Barvergütungen gewährt wird, erhöht seinen direkten Besitz auf 154.216 Aktien. Es wurden keine Käufe, Verkäufe oder Derivatgeschäfte am offenen Markt offengelegt, was darauf hinweist, dass die Meldung eine routinemäßige Governance-Angelegenheit und kein Signal für Insiderstimmung ist.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Goldberg Michael

(Last) (First) (Middle)
C/O CAREDX, INC.
8000 MARINA BOULEVARD

(Street)
BRISBANE CA 94005

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CareDx, Inc. [ CDNA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/08/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/08/2025 A 1,218(1) A $0 154,216 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents an automatic quarterly grant of common stock to the Reporting Person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy.
/s/ Michael Goldberg 07/08/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction was reported for CDNA on July 8, 2025?

Director Michael Goldberg received 1,218 shares of CareDx common stock as an automatic quarterly equity grant.

How many CareDx shares does Michael Goldberg now own?

Following the grant, he beneficially owns 154,216 shares directly.

Was the equity grant executed under a Rule 10b5-1 trading plan?

No. The filing shows a routine compensation grant and does not reference a Rule 10b5-1 plan.

Did the Form 4 disclose any sales or derivative transactions?

No. The report lists no sales or derivative security activity.

What price was paid per share for the grant?

The shares were issued at $0 because they represent compensation, not an open-market purchase.
Caredx

NASDAQ:CDNA

CDNA Rankings

CDNA Latest News

CDNA Latest SEC Filings

CDNA Stock Data

1.15B
53.81M
3.37%
94.9%
9.34%
Diagnostics & Research
Services-medical Laboratories
Link
United States
BRISBANE